Transgene anticipates significant progress from immunotherap

2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation activity to...

Related Keywords

France , Ottawa , Ontario , Canada , John Felitti , Frazer Hall Sylvie Berrebi , Lucie Larguier , Christelle Schwoerer , Maud Brandely Talbot , Christophe Ancel , Transgene Euronext , Johnc Bell , Carol Stuckley , Pedro Romero , James Wentworth , Alessandro Riva , Canadian Oncolytic Virus Consortium , Twitter , Linkedin , Merck Co , Transgene Management Committee , Astrazeneca , University Of Lausanne , Euronext Paris , European Journal , Phasei Delivir , Management Committee , Chief Executive Officer , Chief Scientific Officer , Chief Pharmaceutical Operations Officer , Qualified Pharmacist , Chief Medical , Regulatory Officer , Chief Financial Officer , Chief Business Officer , General Counsel , Corporate Secretary , Chief Human Resources Officer , Combined General Meeting , Senior Scientist , Cancer Therapeutics Program , Ottawa Hospital Research Institute , Tasly Biopharmaceuticals , Artificial Intelligence , Risk Factors , Universal Registration Document , Management Discussion , Markets ,